Amikacin (BAY416651): Mechanism, Resistance, and Research Utility

Executive Summary: Amikacin (BAY416651) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A, with a molecular weight of 585.6 and the formula C₂₂H₄₃N₅O₁₃ (source: product_spec). It exerts bactericidal effects by binding to bacterial 30S ribosomal subunits, inhibiting protein synthesis (source: workflow_recommendation). Amikacin is uniquely resistant to most aminoglycoside-modifying enzymes, except for the AAC(6')-I type, which can confer resistance (source: workflow_recommendation). In recent studies, carbapenem-resistant Enterobacter cloacae isolates showed high prevalence of carbapenemase-encoding genes, contributing to multidrug resistance (source: Chen et al., 2025). APExBIO provides Amikacin (BAY416651) as a research reagent for advanced antibiotic resistance studies (source: product_spec).

Biological Rationale

Amikacin (BAY416651) is widely used in laboratory studies of bacterial resistance, owing to its robust activity against Gram-negative pathogens, including multidrug-resistant strains of Enterobacter cloacae and Klebsiella pneumoniae (source: Chen et al., 2025). The increased prevalence of carbapenem-resistant Enterobacteriaceae (CRE), especially in hospital settings, has heightened the need for research tools capable of dissecting resistance mechanisms (source: workflow_recommendation). Amikacin's stability and enzyme resistance profile make it an essential reference compound in these studies.

Mechanism of Action of Amikacin (BAY416651) Aminoglycoside Antibiotic

Amikacin exerts its antibacterial effect by binding to the 30S subunit of the bacterial ribosome, interfering with the initiation complex formation and causing misreading of mRNA (source: workflow_recommendation). This leads to inhibition of protein synthesis and ultimately cell death. Unlike gentamicin and tobramycin, Amikacin is resistant to most aminoglycoside-modifying enzymes, though the AAC(6')-I enzyme can acetylate it, leading to reduced efficacy in certain strains (source: workflow_recommendation). This property is critical for dissecting resistance pathways in laboratory models.

Evidence & Benchmarks

• Amikacin (BAY416651) remains active against most aminoglycoside-modifying enzyme-producing organisms, except those expressing AAC(6')-I (source: workflow_recommendation).
• In a 2022–2024 study, 85.19% of carbapenem-resistant Enterobacter cloacae isolates harbored carbapenemase-encoding genes, with blaNDM-1 present in 33.33% on both chromosomes and plasmids (source: Chen et al., 2025).
• Resistance rates to aminoglycosides, including gentamicin, were significantly higher in CEG-positive strains than in CEG-negative strains (source: Chen et al., 2025).
• Amikacin is soluble in water at concentrations ≥5.86 mg/mL but insoluble in ethanol and DMSO (source: product_spec).
• Prompt use of aqueous solutions is recommended for optimal stability; long-term storage of solutions is discouraged (source: product_spec).

For a more detailed molecular mechanism and protocol enhancements, see Amikacin (BAY416651): Molecular Mechanisms and Experiment.... This article extends previous work by providing updated prevalence data and cross-laboratory benchmarks.

For workflows focusing on resistance research, Amikacin (BAY416651): Applied Protocols for Resistance Research offers practical troubleshooting strategies, while the current article details the biochemical rationale and evidence base.

Applications, Limits & Misconceptions

Amikacin (BAY416651) is primarily intended for research use in the study of antibiotic resistance mechanisms, especially in multidrug-resistant Enterobacter cloacae and Klebsiella pneumoniae (source: workflow_recommendation). It is not approved for clinical or diagnostic use (source: product_spec).

Common Pitfalls or Misconceptions

• Amikacin is not universally resistant to all aminoglycoside-modifying enzymes; AAC(6')-I can confer resistance in some strains (source: workflow_recommendation).
• Long-term storage of Amikacin solutions can lead to degradation and reduced potency (source: product_spec).
• It should not be used for therapeutic or diagnostic purposes in humans or animals (source: product_spec).
• Effectiveness in vitro does not guarantee efficacy against all multi-drug resistant isolates due to evolving resistance mechanisms (source: Chen et al., 2025).

Workflow Integration & Parameters

Protocol Parameters

• Preparation of stock solution | ≥5.86 mg/mL in water | Aqueous solubility for all research applications | Ensures accurate dosing and repeatability | product_spec
• Storage temperature | -20°C (dry solid) | All bench and storage settings | Maintains compound stability | product_spec
• Solution use window | Immediate or short-term | For aqueous solutions only | Prevents compound degradation | workflow_recommendation
• Resistant enzyme screening | AAC(6')-I presence | Bacterial resistance research | Identifies possible Amikacin resistance | workflow_recommendation
• Incubation for stock dissolution | 37°C for 10 min or ultrasonic shaking | When preparing high-concentration stocks | Ensures full dissolution without degradation | product_spec

Conclusion & Outlook

Amikacin (BAY416651), as supplied by APExBIO, remains a cornerstone in the investigation of bacterial protein synthesis inhibition and resistance mechanisms. Its unique resistance profile enables precise studies of multidrug-resistant Enterobacter cloacae and Klebsiella pneumoniae. Recent epidemiological evidence underscores the escalating prevalence of carbapenemase-encoding genes, motivating robust, reproducible research using validated compounds like Amikacin. The outlook for Amikacin in resistance research remains strong, provided protocols account for its specific stability and susceptibility boundaries (source: Chen et al., 2025).

For further workflow enhancements and advanced protocol guidance, see Amikacin (BAY416651): Applied Workflows in Resistance Research, which this article updates with recent multi-site resistance findings.

For ordering and detailed specifications, refer to the Amikacin (BAY416651) Aminoglycoside Antibiotic product page.